1 August 2017
Rare mutations in the amyloid precursor protein (APP) have previously been shown to be strongly associated with Alzheimer’s disease (AD). Common genetic variants in this protein may also be linked to intelligence (IQ) in children, according to recent research performed at the University of Bergen, Norway.
1 August 2017
Currently, no possibility exists to reliably quantify the risk of Alzheimer’s disease (AD) onset in the general population and in subjects with mild cognitive impairment. Metabolic and genetic factors involved in increasing the probability of developing dementia have already been identified. Some vascular risk factors, as hypertension, dyslipidaemia, diabetes or smoking can cause a derangement in extra or intracranial vessels architecture, which can be responsible for an early aging of the brain. However, reliable tools for early identification of subjects at greater risk of evolution from mild cognitive impairment to AD are not available.
6 July 2017
Dedicated to the study of Alzheimer’s disease, University of Virginia biology professor George Bloom’s lab has spent the last decade working to expand the scientific community’s still-primitive understanding of the disease’s underlying biology. A recently published study from Bloom’s lab is helping to solve one of the devastating brain disorder’s underlying mysteries, explaining how certain proteins convert previously healthy nerve cells into neurons afflicted with Alzheimer’s.
28 June 2017
In the last decade, mounting evidence has linked seizure-like activity in the brain to some of the cognitive decline seen in patients with Alzheimer’s disease. Patients with Alzheimer’s disease have an increased risk of epilepsy and nearly half may experience subclinical epileptic activity – disrupted electrical activity in the brain that doesn’t result in a seizure but which can be measured by electroencephalogram (EEG) or other brain scan technology.
27 June 2017
JAD is pleased to announce that Shi-Jiang Li, PhD, Professor of Biophysics, Radiology, and Psychiatry and Behavioral Medicine at the Medical College of Wisconsin, has been chosen as the recipient of the 2017 Alzheimer Award. It has been presented by the journal in recognition of his outstanding work on the development of the CARE index, potentially a significant new tool in the battle against Alzheimer’s disease (AD) that can be used to characterize risks associated with AD stages and quantify disease severity on an individual subject basis.
21 June 2017
People at risk for Alzheimer’s disease who do more moderate-intensity physical activity, but not light-intensity physical activity, are more likely to have healthy patterns of glucose metabolism in their brain, according to a new UW-Madison study.
15 June 2017
Swedish researchers report in an article published in the Journal of Alzheimer's Disease that 46% of patients who are diagnosed with Alzheimer´s disease in Sweden live alone in their homes, in particular older women.
8 June 2017
Culprit hidden in plain sight in Alzheimer’s disease development: Combustion-derived nanoparticles in key brain target cells and organelles in young urbanites
A new study by researchers at the University of Montana, Universidad del Valle de México, Instituto Nacional de Pediatría, Boise State, and Universidad Nacional Autónoma de México, heightens concerns over the detrimental short- and long-term impact of airborne iron-rich strongly magnetic combustion-derived nanoparticles (CDNPs) present in young urbanites’ brains. The researchers documented by abundant combustion nanoparticles in neurons, glial cells, choroid plexus, and neurovascular units of Mexico City children, teens and young adults chronically exposed to concentrations above the US-EPA standards for fine particulate matter.
1 June 2017
A phase 2 clinical trial in young adults with Down syndrome of a drug being investigated for the treatment of Alzheimer’s disease supports further investigation of its potential. Results of the four-week trial of scyllo-inositol, also known as ELND005, have been published in the Journal of Alzheimer’s Disease.
19 May 2017
The incidence of Alzheimer’s disease (AD) is expected to triple in the coming decades and no cure has been found. Recently, interest in dietary approaches for prevention of cognitive decline has increased. In particular, the omega-3 fatty acids have shown anti-amyloid, anti-tau and anti-inflammatory actions in the brains of animals. In a new article published in the Journal of Alzheimer’s Disease, researchers have found that for patients with high omega-3 levels, blood flow in specific areas of the brain is increased.